



Super-FRS EC meeting
December 2022






Status: G-PAC proposals S469

“Accurate slowing-down measurements of heavy ions (Xe, Pb, U) in gases and solids in the kinetic energy range of (30 to 300) MeV/u with the high-resolution magnetic spectrometer FRS”

S. Purushothaman (Spokesperson)¹, H. Geissel (Co-Spokesperson)^{1,2}, H. Weick (Co-Spokesperson)¹, S. Bagchi¹, T. Dickel², P. Egelhof¹, T. Grahn³, E. Haettner¹, A. Jokinen³, B. Kindler¹, G. Kraft¹, N. Kuzminchuk-Feuerstein¹, B. Lommel¹, C.C. Montanari⁴, Z. Patyk⁵, S. Pietri¹, Y. Pivovarov⁶, W.R. Plaß¹, A. Prochazka¹, C. Scheidenberger^{1,2}, V.P. Shevelko⁸, D. Severin¹, P. Sigmund⁷, A. Sørensen⁹, T. Stöhlker¹, Y. K. Tanaka¹, B. Voss¹, J.S. Winfield¹, M. Winkler¹
& Super-FRS experiment collaboration

1 GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany, 2 Justus-Liebig-Universität Gießen, Germany, 3 University of Jyväskylä, Finland, 4 Universidad de Buenos Aires, Argentina, 5 National Centre for Nuclear Research, Hoża 69, 00-681 Warszawa, Poland, 6 Tomsk Polytechnic University, Tomsk, Russia,
7 University of Southern Denmark, Odense M, Denmark, 8 P. N. Lebedev Physical Institute, Moscow 119991, Russia 9 University of Aarhus, Aarhus C, Denmark


The experiment



Projectile from SIS-18
^{208}Pb
35, 50, 70, 100, 280 MeV/u

Targets	
2 - 327 mg/cm ²	2 - 524 mg/cm ²
Gases	Solids
$^7\text{N}_2$	^6C
^{18}Ar	^{22}Ti
^{36}Kr	^{40}Zr
^{54}Xe	^{50}Sn
C_3H_6	$(\text{C}_3\text{H}_6)_n$

$\sim 400 B\rho$ settings
for ~ 800 spectra!!




What are we interested in?

- Very heavy ions: ^{238}U , ^{209}Bi , ^{208}Pb
- Involvement of **many charge states q** , which complicates theoretical predictions.
- The experimental data are **scarce**.
- The gas-solid difference** has been ignored in theory.

Main results


- For the first time, both the mean charge states and stopping powers of ^{208}Pb ions at 35-280 MeV/u in gases and solids have been measured simultaneously with an accuracy of 1%.
- The Bohr-Lindhard density effect for stopping powers is unambiguously verified in the energy range of the present experiment.
- When the projectiles are nearly fully ionized the gas-solid difference vanishes.
- An unprecedented accuracy of better than 3 % has been achieved when the measured mean charge-states are implemented in the Lindhard Sørensen theory.



Graphenic Carbon Vacuum Windows

Major achievement of S4609 proposal: Stopping Powers of Gases Measured with <1% Accuracy

Thickness < 1 μm and can handle a 1-bar differential pressure.



High accuracy measurement of graphenic carbon stopping power using alpha particle energy loss measurements

Konstantina Botsiou, Master Thesis, TU Darmstadt (2024)

Outlook

Publication status

Physics Department Award, Tohoku University – Best Doctoral Thesis 2021

Accurate Measurements of the Gas-Solid Difference in Stopping-Powers and Charge-State Distributions of Lead Ions in the Energy Range of (30-300) MeV/u

(鉛イオンビームを用いた核子あたり30-300 MeV/u領域における阻止能と荷電状態分布に現れるGas-Solid Differenceの精密測定)


Doctoral Dissertation

by

Shunki ISHIKAWA

Department of Physics
Graduate School of Science
Tohoku University

2021



What is still to be done

- Publish the extensive data on charge-state distribution and stopping power measured during this experiment (Ar - Ti, Xe - Sn, C₃H₆ - (C₃H₆)_n).
 - This data is analysed as part of Shunki Ishikawa's doctoral thesis.
- Analyse and publish the straggling data.
- Use the charge-state measurements to extend and validate the computer code ETACHA.
 - ETACHA is the only charge-state simulation code that accounts for the temporary population of excited states during target passage.





Status: G-PAC proposals S533

“Measurements of nuclear and atomic interactions needed for ion-beam therapy with positron emitters of carbon and oxygen”

S. Purushothaman (Spokesperson)¹, E. Haettner (Co-Spokesperson) ¹, M. Durante (BARB PI) ^{1,2}, P. Dendooven³, H. Geissel^{1,4}, C. Scheidenberger^{1,4}, B. Franczak¹, H. Weick¹, D. Boscolo¹, C. Graeff¹, F. Horst¹, C. Schuy¹, U. Weber¹, J. Äystö^{5,6}, S. Bagchi¹, T. Dickel^{1,4}, V. Drozd^{1,3}, T. Grahn^{5,6}, J.-P. Hucka^{1,2}, M.N. Harakeh³, C. Hornung^{1,4}, F. Greiner¹, N. Kalantar-Nayestanaki³, E. Kazantseva¹, R. Knöbel¹, D. Kostyleva^{1,4}, N. Kuzminchuk-Feuerstein¹, B. Lommel¹, I. Mukha¹, C. Nociforo¹, K. Parodi⁷, S. Pietri¹, W.R. Plaß^{1,4}, A. Prochazka⁸, H. Roesch^{1,2}, M. Safari⁷, F. Schirru¹, H. Simon¹, Y. K. Tanaka⁹, I. Tanihata^{10,11,12}, P. Thirolf⁷, B. Voss¹, M. Winkler¹, J. Zhao^{1,11} and the **Super-FRS Experiment Collaboration**.

1 GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany , 2 TU Darmstadt, Germany , 3 University of Groningen, Groningen, the Netherlands , 4 JLU Gießen, Germany, 5 University of Jyväskylä, Jyväskylä, Finland , 6 Helsinki Institute of Physics, Finland , 7 Ludwig-Maximilians Universität München, Germany , 8 Medaustron, Wiener Neustadt, Austria, 9 RIKEN High Energy Nuclear Physics Laboratory, Japan , 10 RCNP, Osaka University, Mihogaoka, Ibaraki, Osaka, Japan , 11 Beihang University, Beijing, China , 12 Institute of Modern Physics, Lanzhou, China






February 2021 - C block

- Total interaction and charge-changing cross-section of $^{10,11,12}\text{C}$ in carbon, water, PE and Be
- In-beam PET imaging of isotopically pure $^{10,11,12}\text{C}$ implanted in PMMA and PE phantoms


June 2021 - O block

- Charge-changing cross-section of $^{14,15,16}\text{O}$ in carbon, Water, PE
- In-beam PET imaging of isotopically pure $^{14,15,16}\text{O}$ implanted in PMMA and PE phantoms

PET imaging at FRS



Purushothaman, Sivaji, et al., Sci Rep 13, 18788 (2023)
Kostyleva, Daria, et al. Phys. Med. Biol. 1 (2023)




1/6th of a Siemens Biograph mCT clinical scanner
Peter Dendooven





Evaluation of the positron activity: Peak position and its uncertainty

2D PET image of ^{14}O after 4 implantation cycles




Cumulative positron activity profiles 1D activity profiles during irradiation




Quasi-real-time range monitoring

Which is the best positron emitting therapy beam



◆ ^{14}O
● ^{15}O
Beam ON: 1 s
Beam OFF: 1.5 s
◆ ^{10}C
● ^{11}C
Beam ON: 2 s
Beam OFF: 2.8 s



Publication status

scientific reports

OPEN Quasi-real-time range monitoring by in-beam PET: a case for ^{15}O

S. Purushothaman^{1,2}, D. Kostyleva³, P. Dendooven⁴, E. Haettner⁵, H. Geissel^{1,3}, C. Schuy⁶, U. Weber⁶, D. Boscolo⁷, T. Dickey^{8,9}, C. Graeff^{1,3}, C. Hornung¹, E. Kazantseva³, N. Kuzminchuk-Feuerstein¹, I. Mukha¹, S. Pietri¹⁰, H. Roessch¹¹, Y. K. Tanaka⁸, J. Zhao^{1,2}, M. Durante^{1,2,12}, K. Parodi¹ & C. Scheidenberger^{1,3}

A fast and reliable range monitoring method is required to take full advantage of the high linear energy transfer provided by therapeutic ion beams like carbon and oxygen while minimizing damage to healthy tissue due to range uncertainties. Quasi-real-time range monitoring using in-beam positron emission tomography (PET) with therapeutic beams of positron-emitters of carbon and oxygen is a promising approach. The number of implanted ions and the time required for an unambiguous range verification to decide factors for choosing a candidate setting. An experimental study was performed at the FRS fragment separator of GSI Helmholtzzentrum für Schwerionenforschung eV (GSI), Germany, to investigate the feasibility of positron annihilation depth profiles during the implantation of ^{15}O and ^{13}C on a PMMA phantom. The position activation profile was imaged by a dual-panel version of a Siemens Biograph mCT PET scanner. Results from a similar experiment using ion beams of carbon positron-emitters ^{13}C and ^{11}C performed at the same experimental setup were used for comparison. Owing to their shorter half-lives, the number of implanted ions required for a precise position annihilation activity peak determination is lower for ^{13}C compared to ^{15}O and likewise for ^{11}C compared to ^{13}C , but the lower production cross-section makes it difficult to produce them at the same rate. The results show that the use of ^{15}O instead of ^{13}C and ^{11}C provides a faster conclusive positron annihilation activity peak position determination for a lower number of implanted ions compared to ^{13}C . A figure of merit formulation was developed for the quantitative comparison of therapy-relevant positron-in-beam in the context of quasi-real-time beam monitoring. In conclusion, this study demonstrates that among the positron emitters of carbon and oxygen, ^{15}O is the most feasible candidate for quasi-real-time range monitoring by in-beam PET that can be produced at therapeutically relevant intensities. Additionally, this study demonstrated that in-flight production and separation method can produce beams of therapeutic quality, in terms of purity, energy, and energy spread.

Proton therapy is currently the most widespread type of ion beam therapy. The rationale behind using ions heavier than protons for radiation therapy is the reduced lateral scattering with increasing ion mass and the higher linear energy transfer (LET). However, proton therapy is not the only alternative. Carbon therapy has a downside characterized by higher investment costs, typically ranging from 2 to 4 times more expensive and the cost per treatment of carbon ions is about 2–3 times higher than that of conventional therapy with X-rays. Additionally, the heavy ions have the issue of unavoidable projectile fragmentation, which leads to an undesirable dose tail distal to the target. Carbon has been identified as an excellent compromise ion due to its favorable characteristics. It exhibits the best ratio of biologically effective dose to the entrance dose for the entrance channel for numerous indications. Consequently, carbon is presently the most widely utilized ion at all light ion

GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany. ²Department of Radiation Oncology, Particle Therapy Research Center (PARTPEC), University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. ³Institute for Applied Physics, Technische Universität Darmstadt, Darmstadt, Germany. ⁴RIKEN Cluster for Pioneering Research, RIKEN, Wako, Japan. ⁵School of Physics, Beijing University, Beijing, China. ⁶Department of Condensed Matter Physics, Technische Universität Darmstadt, Darmstadt, Germany. ⁷Department of Nuclear Physics, Faculty of Physics, Ludwig-Maximilians-Universität München, Munich, Germany. ⁸RIKEN Cluster for Advanced Materials Research for FAIR (HFR), Campus Gifhorn, Gifhorn, Germany. ⁹E-mail address: m.durante@gsi.de. ¹⁰Corresponding author. E-mail address: d.kostyleva@gsi.de. ¹¹Received 9 May 2022; received in revised form 1 September 2022; accepted 2 September 2022. Available online 15 September 2022. Published by Elsevier B.V. This is an open access article under the CC BY-NC license. <https://doi.org/10.1016/j.srep.2022.147464>

www.nature.com/scientificreports/



Nuclear Inst. and Methods in Physics Research, A 1043 (2022) 167464
Contents lists available at ScienceDirect
journal homepage: www.elsevier.com/locate/nima

Depth dose measurements in water for ^{11}C and ^{10}C beams with therapy relevant energies

Daria Boscolo¹, Daria Kostyleva¹, Christoph Schuy², Uli Weber², Emma Haettner³, Svetlana Purushothaman⁴, Peter Dendooven⁵, Timo Dickey^{6,7}, Vasilij Droud⁸, Bernhard Franzck⁹, Hans Geissel¹⁰, Christine Hornung¹¹, Felici Horst¹², Erika Kazantseva¹³, Natalia Kuzminchuk-Feuerstein¹⁴, Giulio Lovatti¹⁵, Ivan Mukha¹⁶, Chiara Noziforo¹⁷, Stefanie Pietri¹⁸, Marco Pinto¹⁹, Claire-Anne Reitfeld²⁰, Heidi Roesch^{21,22}, Olga Sokol²³, Yoshiaki K. Tanaka²⁴, Helmut Weick²⁵, Jianwei Zhao²⁴, Christoph Scheidenberger^{1,3}, Katja Pohl²⁶, Marco Durante^{1,2}

¹GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany

²Justus-Liebig-Universität Gießen, Gießen, Germany

³Institut für Angewandte Physik, Gießen, Germany

⁴RIKEN Cluster for Pioneering Research, Wako, Japan

⁵Technische Universität Darmstadt, Darmstadt, Germany

⁶RIKEN High Energy Nuclear Physics Laboratory, Wako, Japan

⁷Fudan University, Shanghai, China

⁸Ludwig-Maximilians-Universität München, Munich, Germany

ARTICLE INFO

Keywords:

Ion beam therapy
Range therapy
Range monitoring
Carbon ions

ABSTRACT

Owing to the favorable depth-dose distribution and the radiobiological properties of heavy ion radiation, ion beam therapy shows an improved accuracy-treatment ratio compared to conventional radiotherapy. The sharp dose gradient and very high doses in the Bragg peak region, which represent the physical advantage of ion beam therapy, make it also extremely sensitive to range uncertainties. The use of β^+ -radioactive ion beams would be ideal for simultaneous treatment and accurate online range monitoring through PET imaging. Together with the underground, primary ions are potentially contributing to the total signal of the beam, together with secondary particles and fragments. The range uncertainty of the stable counterparts, the challenging production of radioactive ion beams and the difficulties in reaching high intensities, have discouraged their clinical application. In this context, the project Biomedical Applications of Radioactive Ion Beams (BARI) at GSI Helmholtzzentrum für Schwerionenforschung (GSI) with the main goal to assess the medical feasibility of radioactive ion beams on pre-clinical level. During the first experimental campaign ^{11}C and ^{10}C beams were produced and isotopically separated at the Fragment Separator (FRS) at GSI. The β^+ -radioactive ion beams were produced with a beam purity of 99% and a dose rate of 100 Gy/min. When a dose of 10 Gy was given, it was necessary to irradiate a small animal tumor for few minutes of irradiation time, i.e., 10^7 particle per spill for the ^{11}C and 10^8 particle per spill for the ^{10}C , respectively. The impact of different ion optical parameters on the depth dose distribution was studied with a precision water column system. In this work, the measured depth dose distributions are presented together with results from Monte Carlo simulations using the FLUKA software.

1. Introduction

The use of β^+ -radioactive ion beams (RIB) such as ^{11}C and ^{10}C , for simultaneous range verification and treatment, could represent a major improvement for heavy ion therapy applications [1–3].

* Corresponding author.
E-mail address: m.durante@gsi.de (M. Durante).

<https://doi.org/10.13145/srep.46464>

Received 9 May 2022; received in revised form 1 September 2022; accepted 2 September 2022. Available online 15 September 2022. Published by Elsevier B.V. This is an open access article under the CC BY-NC license. <https://doi.org/10.1016/j.srep.2022.147464>

IOP Publishing *Phys. Med. Biol.* 68 (2023) 015003 <https://doi.org/10.1088/1361-6560/aca5e8>

Physics in Medicine & Biology

Contents lists available at ScienceDirect
journal homepage: www.elsevier.com/locate/pmedb

IPEM
Institute of Physics and
Engineering in Medicine

PAPER

Precision of the PET activity range during irradiation with ^{10}C , ^{11}C , and ^{12}C beams

D. Kostyleva¹, S. Purushothaman^{1,2}, P. Dendooven³, E. Haettner⁴, H. Geissel^{1,2}, J. Ozorenko^{1,2,3}, C. Schuy⁵, U. Weber⁵, D. Boscolo⁶, T. Dickey^{6,7}, V. Droud⁸, C. Graeff^{1,3}, C. Hornung¹, F. Horst^{1,2,3}, E. Kazantseva¹, N. Kuzminchuk-Feuerstein¹, I. Mukha¹, C. Noziforo¹, S. Pietri¹, C. Reitfeld¹, H. Roesch¹, Y.K. Tanaka⁹, H. Weick¹⁰, J. Zhao¹⁰, M. Durante^{1,2,11}, K. Parodi¹ and Super-FRS Experiment Collaboration¹²

Original content from this work may be used under the terms of the Creative Commons Attribution 4.0 International license, as detailed in the copyright and permission section below.

Accepted 24 November 2022
Published 19 December 2022

© 2022 Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany

© 2022 Physikalisch-Technische Bundesanstalt, Braunschweig, Germany

© 2022 RIKEN Cluster for Pioneering Research, RIKEN, Saitama, Japan

© 2022 Universiteit van Amsterdam, Amsterdam, The Netherlands

© 2022 Faculty of Sciences and Applied Mathematics, University of Groningen, Groningen, The Netherlands

© 2022 Institute for Nuclear Physics, Technische Universität Darmstadt, Darmstadt, Germany

© 2022 RIKEN Cluster for Pioneering Research, Wako, Japan

© 2022 School of Physics, Beijing University, Beijing, People's Republic of China

© 2022 School of Physics, Peking University, Beijing, China

© 2022 Department of Physics, Ludwig-Maximilians-Universität München, München, Germany

© 2022 Helmholtz-Gesellschaft für Strahlen- und Umweltforschung mbH, Berlin, Germany

© 2022 Present address: Radiation Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston Massachusetts, USA

© 2022 Present address: Oncology—Center for Radiation Research in Oncology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution 4.0 International license

© 2022 Authors. *Production and separation of positron emitters for hadron therapy at FRS-Cave M* is licensed under a Creative Commons Attribution

Next Steps and Opportunities

Residual

